The outputs of simulations reflected findings from the clinical trials: Virtual absence of toxicity in the non-ADPKD scenario, and incidences of ALT elevations and potentially serious DILI in the ADPKD scenario. The gene discussed is GPT; the disease is autosomal dominant polycystic kidney disease.